Toggle

Pharmaceuticals



Stream Bio continues European market growth with bioimaging probe launch in Italy through DBA Italia


13/03/2019
Stream Bio has further expanded the European distribution network for its Conjugated Polymer Nanoparticles (CPNsT). A new agreement with DBA Italia will make Stream’s innovative bioimaging probes available for purchase in Italy.
 
Stream Bio’s CPNs represent a new generation of novel molecular bioimaging probes. These highly fluorescent, non-toxic nanoparticles are transforming the bioimaging market with their unique brightness, exceptional stability, magnetic capability and suitability to be conjugated with a wide range of molecules.
 
The launch by DBA Italia, an established and renowned company offering a wide range of reagents for the Italian life sciences market, highlights the continued growth and commercial potential of the CPNs. Stream Bio was also recently awarded an Innovate UK-funded manufacturing and materials loan, which will enable the further expansion of its product range.
 
Available for purchase through DBA Italia as of today, Stream Bio’s CPNs come in four emission wavelengths ranging from 475 - 680 nm, and can now be streptavidin-linked. Stream Bio’s CPNs have applications in diagnostics and therapeutics, and have the potential to be used for imaging tumours and fluorescence-guided surgery.
 
The CPNs are already distributed in the UK and Ireland through 2BScientific, in France through CliniSciences and in Germany through Biotrend.
 
Stream Bio’s, CEO, Andy Chaloner: “We are delighted to further establish Stream Bio’s innovative CPNs presence in the Europe through our arrangement with DBA Italia. It is fantastic to be able to provide Italian researchers with access to the transformative potential of our CPNs.”
 
DBA Italia’s General Manager, Marco d’Erasmo, said: “We are thrilled to include Stream Bio’s CPNs in our portfolio of products. The CPNs have an exciting range of downstream applications for fluorescence, bioimaging and nanotechnology, in the life sciences, biotechnology and Pharma markets. This opens new doors for our customers when developing therapeutic and diagnostic solutions.”